Women who are pregnant or br east feeding. Test product, dose and mode of administration: Each patient will be administered separate intradermal injection s (at the same injection sites) of HS -130 (Lot HBI-HS-130-FP-001: OX40L -Ig concentration = 338 ng OX40L -Ig/106 cells/24 -hr) and HS -110 (Lot 0000748931: gp96- Ig concentration = 104 ng gp96 -Ig/106 cells/24 -hr) based on the dose levels as defined in the dose escalation scheme (Section 6.1.1 ) on Day 1 of each cycle . Dose -limiting toxicity (DLT): Adverse events will be assessed per CTCAE version 5.